Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far

Winston Wong; Emily Alouani; Alexander Wei; Yun Kyoung Ryu; John A. Chabot; Gulam A. Manji

doi:10.1053/j.seminoncol.2021.02.007

Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far

Winston Wong, Emily Alouani, Alexander Wei, Yun Kyoung Ryu, John A. Chabot, Gulam A. Manji

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Pancreas ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival rate of 10%. Currently, chemotherapy remains the standard of care for systemic treatment. Immunotherapy with checkpoint inhibitors unfortunately has not been found to be effective in the treatment of PDAC to date, likely due to the highly desmoplastic and immunosuppressive tumor microenvironment (TME). Treatment targeting pathways against the immunosuppressive mechanisms of PDAC are of mounting interest to improve outcomes in PDAC. In this review, we discuss prior efforts and the current state of immunotherapy in PDAC. We will also review the emerging targets and treatments with significant clinical potential for the treatment of PDAC such as: CD40 pathway, the adenosine pathway, the CXCR4/CXCL12 axis, the CCR2/CCL2 axis, IDO pathway, and others.

Original language	English (US)
Pages (from-to)	57-68
Number of pages	12
Journal	Seminars in oncology
Volume	48
Issue number	1
DOIs	https://doi.org/10.1053/j.seminoncol.2021.02.007
State	Published - Feb 2021
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hematology
Oncology

Keywords

Immunotherapy
Pancreatic cancer

Access to Document

10.1053/j.seminoncol.2021.02.007

Cite this

@article{b05d32d6d49b47738a2d914cc8bc2350,

title = "Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far",

abstract = "Pancreas ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival rate of 10\%. Currently, chemotherapy remains the standard of care for systemic treatment. Immunotherapy with checkpoint inhibitors unfortunately has not been found to be effective in the treatment of PDAC to date, likely due to the highly desmoplastic and immunosuppressive tumor microenvironment (TME). Treatment targeting pathways against the immunosuppressive mechanisms of PDAC are of mounting interest to improve outcomes in PDAC. In this review, we discuss prior efforts and the current state of immunotherapy in PDAC. We will also review the emerging targets and treatments with significant clinical potential for the treatment of PDAC such as: CD40 pathway, the adenosine pathway, the CXCR4/CXCL12 axis, the CCR2/CCL2 axis, IDO pathway, and others.",

keywords = "Immunotherapy, Pancreatic cancer",

author = "Winston Wong and Emily Alouani and Alexander Wei and Ryu, \{Yun Kyoung\} and Chabot, \{John A.\} and Manji, \{Gulam A.\}",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = feb,

doi = "10.1053/j.seminoncol.2021.02.007",

language = "English (US)",

volume = "48",

pages = "57--68",

journal = "Seminars in oncology",

issn = "0093-7754",

publisher = "W.B. Saunders",

number = "1",

}

TY - JOUR

T1 - Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far

AU - Wong, Winston

AU - Alouani, Emily

AU - Wei, Alexander

AU - Ryu, Yun Kyoung

AU - Chabot, John A.

AU - Manji, Gulam A.

PY - 2021/2

Y1 - 2021/2

N2 - Pancreas ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival rate of 10%. Currently, chemotherapy remains the standard of care for systemic treatment. Immunotherapy with checkpoint inhibitors unfortunately has not been found to be effective in the treatment of PDAC to date, likely due to the highly desmoplastic and immunosuppressive tumor microenvironment (TME). Treatment targeting pathways against the immunosuppressive mechanisms of PDAC are of mounting interest to improve outcomes in PDAC. In this review, we discuss prior efforts and the current state of immunotherapy in PDAC. We will also review the emerging targets and treatments with significant clinical potential for the treatment of PDAC such as: CD40 pathway, the adenosine pathway, the CXCR4/CXCL12 axis, the CCR2/CCL2 axis, IDO pathway, and others.

AB - Pancreas ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival rate of 10%. Currently, chemotherapy remains the standard of care for systemic treatment. Immunotherapy with checkpoint inhibitors unfortunately has not been found to be effective in the treatment of PDAC to date, likely due to the highly desmoplastic and immunosuppressive tumor microenvironment (TME). Treatment targeting pathways against the immunosuppressive mechanisms of PDAC are of mounting interest to improve outcomes in PDAC. In this review, we discuss prior efforts and the current state of immunotherapy in PDAC. We will also review the emerging targets and treatments with significant clinical potential for the treatment of PDAC such as: CD40 pathway, the adenosine pathway, the CXCR4/CXCL12 axis, the CCR2/CCL2 axis, IDO pathway, and others.

KW - Immunotherapy

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85105291985&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105291985&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2021.02.007

DO - 10.1053/j.seminoncol.2021.02.007

M3 - Article

C2 - 33965249

AN - SCOPUS:85105291985

SN - 0093-7754

VL - 48

SP - 57

EP - 68

JO - Seminars in oncology

JF - Seminars in oncology

IS - 1

ER -

Future of immunotherapy in pancreas cancer and the trials, tribulations and successes thus far

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this